WILMINGTON, DE / ACCESSWIRE / March 16, 2020 / Rigrodsky & Long, P.A. announces that it is investigating Tetraphase Pharmaceuticals, Inc. ("Tetraphase") (NASDAQ:TTPH) regarding possible breaches of fiduciary duties and other violations of law related to Tetraphase's agreement to be acquired AcelRx Pharmaceuticals, Inc. ("AcelRx") (NASDAQ:ACRX). Under the terms of the agreement, shareholders of Tetrraphase will receive 0.6303 shares of AcelRx for each share of Tetraphase they own, plus a contingent value right (CVR).
To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-tetraphase-pharmaceuticals-inc.
If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242 or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Rigrodsky & Long, P.A.
View source version on accesswire.com: